metformin has been researched along with Atherogenesis in 78 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 9.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
| "We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes." | 9.16 | Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. ( Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A, 2012) |
| "Metformin prevents plaque progression in HIV-infected patients with the metabolic syndrome." | 9.16 | Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. ( Abbara, S; Fitch, K; Grinspoon, S; Hemphill, L; Lee, H; Michel, T; Sacks, R; Stavrou, E; Torriani, M, 2012) |
| "To investigate the preventive action of metformin for atherosclerosis (AS) in patients with type 2 diabetes mellitus (T2DM)." | 9.14 | [Primary preventive effect of metformin upon atherosclerosis in patients with type 2 diabetes mellitus]. ( Ba, Y; Bai, R; Du, JL; Jia, YJ; Men, LL; Xing, Q; Yang, Y; Zhang, XY, 2009) |
| "The aim of this study was to investigate the effects of pioglitazone or metformin on bone mass and atherosclerosis in patients with type 2 diabetes." | 9.14 | Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. ( Kanazawa, I; Kurioka, S; Sugimoto, T; Yamaguchi, T; Yamamoto, M; Yamauchi, M; Yano, S, 2010) |
| "Metformin activates a conserved AMPK-ATF1-M2-like pathway in mouse and human macrophages, and results in highly suppressed atherogenesis in hyperlipidaemic mice via haematopoietic AMPK." | 8.02 | Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase. ( Boyle, JJ; Carling, D; Cave, L; Haskard, DO; Hyde, G; Mason, JC; Moestrup, SK; Seneviratne, A, 2021) |
| "The present study aimed to investigate the effect of metformin on diabetes-accelerated atherosclerosis and whether Nod-like receptor protein 3 (NLRP3) inflammasome is a target for metformin." | 7.91 | Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE ( Chen, Y; Duan, F; Hu, J; Li, H; Li, W; Tan, H; Tang, G; Wang, Y; Zeng, C; Zhang, X, 2019) |
| "Metformin can attenuate early-stage atherogenesis in mildly hyperglycemic ON-DP mice." | 7.91 | Metformin Attenuates Early-Stage Atherosclerosis in Mildly Hyperglycemic Oikawa-Nagao Mice. ( Asai, A; Kawahara, M; Miyazawa, T; Nagao, M; Oikawa, S; Shuto, Y; Sugihara, H, 2019) |
| "The present study aimed to investigate the possible effects of metformin on the progression of atherosclerosis in a rabbit model." | 7.88 | Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses in rabbits. ( Chen, J; Chen, M; Qu, J; Ren, W; Sun, S; Tang, X; Wang, H; Yang, Q; Yu, B; Yuan, H, 2018) |
| "Pleiotropic effects of metformin ameliorate atherosclerosis and vascular senescence." | 7.80 | Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. ( Alexander, RW; Fei, B; Forouzandeh, F; Hilenski, L; Patrushev, N; Salazar, G; Xiong, S, 2014) |
| "In 74 women with polycystic ovary syndrome, treated for 4 years with metformin (MET) and diet, we prospectively assessed whether, and to what degree, weight loss, reduction of insulin resistance, and amelioration of coronary heart disease risk factors could be sustained." | 7.73 | Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "Atherosclerosis is a common cause of cardiovascular disease, which, in turn, is often fatal." | 6.82 | From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease. ( Litvinova, L; Moschetta, D; Orekhov, AN; Poggio, P; Poznyak, AV; Sukhorukov, VN, 2022) |
| "As metformin is an inexpensive agent with an established safety profile, larger scale clinical trials based on hard clinical outcomes [cardiovascular disease (CVD) events] are now indicated." | 6.58 | Metformin, lipids and atherosclerosis prevention. ( Jenkins, AJ; Petrie, JR; Welsh, P, 2018) |
| "Metformin, a first-line treatment for Type 2 diabetes, is reported to be beneficial to cardiovascular disease." | 5.62 | Metformin attenuates atherosclerosis and plaque vulnerability by upregulating KLF2-mediated autophagy in apoE ( Dong, Z; Feng, K; Hua, Y; Ma, C; Wu, H; Yang, S; Zhang, C; Zhang, H; Zhang, J; Zhu, Y, 2021) |
| "Oral metformin supplementation once daily for 24 weeks as an adjuvant therapy to intensive insulin in pediatric T1DM was safe and effective in improving glycemic control, dyslipidemia and Nrg-4 levels; hence, it decreased inflammation, microvascular complications and subclinical atherosclerosis." | 5.51 | Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: A randomized controlled trial. ( Elbarbary, NS; Ghallab, MA; Ismail, EAR, 2022) |
| "While substantial preclinical and clinical evidence suggests metformin as a potential cardiovascular protectant, large-scale randomized controlled trials are warranted to establish its clinical efficacy in treating patients with atherosclerotic cardiovascular disease and heart failure." | 5.41 | Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research. ( Li, JZ; Li, YR, 2023) |
| "Metformin treatment decreases serum ASAA in these women." | 5.37 | The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis. ( Adya, R; Aghilla, M; Keay, SD; Lehnert, H; Randeva, HS; Shan, X; Tan, BK, 2011) |
| "Treatment with metformin significantly attenuated the progression of aortic atherosclerosis." | 5.35 | Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. ( Cheng, X; Deng, HP; Feng, YB; Li, SN; Mao, XB; Wang, TH; Wang, X; Zeng, QT, 2009) |
| " This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 5.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
| "Metformin prevents plaque progression in HIV-infected patients with the metabolic syndrome." | 5.16 | Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. ( Abbara, S; Fitch, K; Grinspoon, S; Hemphill, L; Lee, H; Michel, T; Sacks, R; Stavrou, E; Torriani, M, 2012) |
| "We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes." | 5.16 | Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. ( Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A, 2012) |
| "The aim of this study was to investigate the effects of pioglitazone or metformin on bone mass and atherosclerosis in patients with type 2 diabetes." | 5.14 | Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. ( Kanazawa, I; Kurioka, S; Sugimoto, T; Yamaguchi, T; Yamamoto, M; Yamauchi, M; Yano, S, 2010) |
| "To investigate the preventive action of metformin for atherosclerosis (AS) in patients with type 2 diabetes mellitus (T2DM)." | 5.14 | [Primary preventive effect of metformin upon atherosclerosis in patients with type 2 diabetes mellitus]. ( Ba, Y; Bai, R; Du, JL; Jia, YJ; Men, LL; Xing, Q; Yang, Y; Zhang, XY, 2009) |
| "Metformin activates a conserved AMPK-ATF1-M2-like pathway in mouse and human macrophages, and results in highly suppressed atherogenesis in hyperlipidaemic mice via haematopoietic AMPK." | 4.02 | Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase. ( Boyle, JJ; Carling, D; Cave, L; Haskard, DO; Hyde, G; Mason, JC; Moestrup, SK; Seneviratne, A, 2021) |
| "Trimethylamine-N-oxide (TMAO), a gut-microbiota-dependent metabolite generated from its dietary precursors such as choline, has been identified as an independent risk factor for atherosclerosis." | 4.02 | Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality. ( Du, Y; Hong, B; Li, X; Su, C; Wang, L; Yang, Y; Zhang, X, 2021) |
| "The present study aimed to investigate the effect of metformin on diabetes-accelerated atherosclerosis and whether Nod-like receptor protein 3 (NLRP3) inflammasome is a target for metformin." | 3.91 | Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE ( Chen, Y; Duan, F; Hu, J; Li, H; Li, W; Tan, H; Tang, G; Wang, Y; Zeng, C; Zhang, X, 2019) |
| "Metformin can attenuate early-stage atherogenesis in mildly hyperglycemic ON-DP mice." | 3.91 | Metformin Attenuates Early-Stage Atherosclerosis in Mildly Hyperglycemic Oikawa-Nagao Mice. ( Asai, A; Kawahara, M; Miyazawa, T; Nagao, M; Oikawa, S; Shuto, Y; Sugihara, H, 2019) |
| "Co-treatment with T317 and metformin inhibited the development of atherosclerosis without activation of lipogenesis, suggesting that combined treatment with T317 and metformin may be a novel approach to inhibition of atherosclerosis." | 3.88 | Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy. ( Chen, Y; Duan, Y; Feng, K; Han, J; Hu, W; Li, L; Li, X; Liu, L; Liu, Y; Ma, C; Miao, RQ; Sun, L; Yang, J; Yang, S; Yang, X; Yu, M; Zhang, W; Zhang, X; Zhu, Y, 2018) |
| "The present study aimed to investigate the possible effects of metformin on the progression of atherosclerosis in a rabbit model." | 3.88 | Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses in rabbits. ( Chen, J; Chen, M; Qu, J; Ren, W; Sun, S; Tang, X; Wang, H; Yang, Q; Yu, B; Yuan, H, 2018) |
| "Laboratory studies suggest that metformin limits atherosclerosis." | 3.80 | The cardiovascular effects of metformin: lost in translation? ( Riksen, NP; Tack, CJ, 2014) |
| "Pleiotropic effects of metformin ameliorate atherosclerosis and vascular senescence." | 3.80 | Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. ( Alexander, RW; Fei, B; Forouzandeh, F; Hilenski, L; Patrushev, N; Salazar, G; Xiong, S, 2014) |
| "In 74 women with polycystic ovary syndrome, treated for 4 years with metformin (MET) and diet, we prospectively assessed whether, and to what degree, weight loss, reduction of insulin resistance, and amelioration of coronary heart disease risk factors could be sustained." | 3.73 | Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "Adolescents with type 1 diabetes have early macrovascular changes (increased intima-media thickness [IMT]) and early retinal changes that predict clinical disease in adulthood." | 2.87 | Early atherosclerosis is associated with retinal microvascular changes in adolescents with type 1 diabetes. ( Anderson, J; Couper, JJ; Gent, R; Giles, LC; Liew, G; Peña, AS; Wong, TY, 2018) |
| "Atherosclerosis is a common cause of cardiovascular disease, which, in turn, is often fatal." | 2.82 | From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease. ( Litvinova, L; Moschetta, D; Orekhov, AN; Poggio, P; Poznyak, AV; Sukhorukov, VN, 2022) |
| "The global epidemic of type 2 diabetes has prompted numerous studies and public health efforts to reduce its development." | 2.61 | Does diabetes prevention translate into reduced long-term vascular complications of diabetes? ( Bennett, PH; Crandall, JP; Edelstein, SL; Goldberg, RB; Kahn, SE; Knowler, WC; Mather, KJ; Mudaliar, S; Nathan, DM; Orchard, TJ; Temprosa, M; White, NH, 2019) |
| "As metformin is an inexpensive agent with an established safety profile, larger scale clinical trials based on hard clinical outcomes [cardiovascular disease (CVD) events] are now indicated." | 2.58 | Metformin, lipids and atherosclerosis prevention. ( Jenkins, AJ; Petrie, JR; Welsh, P, 2018) |
| "Obesity is associated with development of adipose tissue inflammation." | 2.45 | [Adipose tissue inflammation and atherosclerosis]. ( Shwarts, V, 2009) |
| "Metformin has so far consistently succeeded in reducing cardiovascular morbidity and mortality and exerting beneficial effects on lipids." | 2.45 | Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? ( Maltezos, E; Papanas, N, 2009) |
| "Metformin has long been known to reduce the development of atherosclerotic lesions in animal models, and clinical studies have shown the drug to reduce surrogate measures such as carotid intima-media thickness." | 2.44 | Metformin: effects on micro and macrovascular complications in type 2 diabetes. ( Bailey, CJ, 2008) |
| "Atherosclerosis is a persistent inflammatory state that contributes significantly to cardiovascular disease, a primary cause of mortality worldwide." | 1.91 | AMPK activators suppress cholesterol accumulation in macrophages via suppression of the mTOR pathway. ( Aoki, H; Aoyama, M; Hayashi, H; Inoue, Y; Kakita, H; Owaki, R; Takeshita, S; Toriuchi, K; Yamada, Y, 2023) |
| "Metformin, a first-line treatment for Type 2 diabetes, is reported to be beneficial to cardiovascular disease." | 1.62 | Metformin attenuates atherosclerosis and plaque vulnerability by upregulating KLF2-mediated autophagy in apoE ( Dong, Z; Feng, K; Hua, Y; Ma, C; Wu, H; Yang, S; Zhang, C; Zhang, H; Zhang, J; Zhu, Y, 2021) |
| "Patients with type 2 diabetes and carotid artery disease were included into the study prospectively." | 1.51 | Effect of metformin treatment in patients with type 2 diabetes with respect to glyoxalase 1 activity in atherosclerotic lesions. ( Böckler, D; Bruckner, T; Fleming, TH; Hakimi, M; Nawroth, PP; Peters, AS; Wortmann, M, 2019) |
| "We enrolled 176 individuals with type 2 diabetes, which were divided into four treatment groups according to different oral drugs: metformin alone, sitagliptin alone, pioglitazone alone, or combination of metformin and sitagliptin." | 1.46 | Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients. ( Chen, W; Liu, X; Mei, T; Ye, S, 2017) |
| "Atherosclerosis is known to be the primary underlying factor responsible for the development of cardiovascular diseases." | 1.46 | Comparative transcriptomic analysis of mice liver treated with different AMPK activators in a mice model of atherosclerosis. ( An, Y; Fang, W; Ma, A; Wang, D; Zhu, H, 2017) |
| "Metformin is a cornerstone of the current therapy of type 2 diabetes." | 1.40 | Metformin affects macrophages' phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages. ( Bułdak, RJ; Bułdak, Ł; Duława-Bułdak, A; Kozłowski, M; Liber, S; Machnik, G; Okopień, B; Suchy, D; Łabuzek, K, 2014) |
| "Vitamin D deficiency is now linked to several conditions including increased risk of CV disorders, diabetes, etc." | 1.40 | A multimodal Darwinian strategy for alleviating the atherosclerosis pandemic. ( Mathew, G; Thambi, M; Unnikrishnan, MK, 2014) |
| "Individuals with type 2 diabetes (T2DM) are at increased risk of cardiovascular disease, including heart failure (HF)." | 1.39 | Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes. ( Czlonkowski, A; Filipiak, KJ; Kaplon-Cieslicka, A; Opolski, G; Postula, M; Rosiak, M; Trzepla, E, 2013) |
| "Metformin treatment decreases serum ASAA in these women." | 1.37 | The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis. ( Adya, R; Aghilla, M; Keay, SD; Lehnert, H; Randeva, HS; Shan, X; Tan, BK, 2011) |
| "Hyperlipidemia, thrombosis and oxidative stress are the primary underlying concerns in the pathogenesis of atherosclerosis." | 1.37 | Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats. ( Bhadada, SV; Dhamecha, PS; Ghatak, SB; Panchal, SJ, 2011) |
| "Metformin was administered to all patients for 16 weeks." | 1.36 | Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. ( Chen, LL; Hu, LJ; Li, YM; Liao, YF; Zeng, TS, 2010) |
| "Treatment with metformin significantly attenuated the progression of aortic atherosclerosis." | 1.35 | Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. ( Cheng, X; Deng, HP; Feng, YB; Li, SN; Mao, XB; Wang, TH; Wang, X; Zeng, QT, 2009) |
| "Pre-treatment with metformin (100-1000 micromol/L) also inhibited TNF-alpha-induced IL-6 production, phosphorylation of IkappaB kinase (IKK) alpha/beta and IkappaB-alpha degradation." | 1.35 | Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. ( Chen, YJ; Chiang, SH; Hsueh, CH; Huang, NL; Lai, LP; Liang, YJ, 2009) |
| "Pretreatment with metformin also decreased phosphorylation of Akt and protein kinase C (PKC) in ECs under these conditions." | 1.33 | Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. ( Gerdes, N; Isoda, K; Libby, P; MacFarlane, LA; Schönbeck, U; Tsuboi, N; Young, JL; Zirlik, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (17.95) | 29.6817 |
| 2010's | 48 (61.54) | 24.3611 |
| 2020's | 16 (20.51) | 2.80 |
| Authors | Studies |
|---|---|
| Azemi, AK | 1 |
| Mokhtar, SS | 1 |
| Sharif, SET | 1 |
| Rasool, AHG | 1 |
| Elbarbary, NS | 1 |
| Ismail, EAR | 1 |
| Ghallab, MA | 1 |
| Kuzan, A | 1 |
| Królewicz, E | 1 |
| Kustrzeba-Wójcicka, I | 1 |
| Lindner-Pawłowicz, K | 1 |
| Sobieszczańska, M | 1 |
| Gillani, SW | 1 |
| Syed Sulaiman, SA | 1 |
| Menon, V | 1 |
| Rahamathullah, N | 1 |
| Elshafie, RM | 1 |
| Rathore, HA | 1 |
| Poznyak, AV | 1 |
| Litvinova, L | 1 |
| Poggio, P | 1 |
| Moschetta, D | 1 |
| Sukhorukov, VN | 1 |
| Orekhov, AN | 1 |
| Xie, D | 1 |
| Li, Y | 3 |
| Xu, M | 1 |
| Zhao, X | 1 |
| Chen, M | 2 |
| Li, JZ | 1 |
| Li, YR | 1 |
| Owaki, R | 1 |
| Aoki, H | 1 |
| Toriuchi, K | 1 |
| Inoue, Y | 1 |
| Hayashi, H | 1 |
| Takeshita, S | 1 |
| Kakita, H | 1 |
| Yamada, Y | 1 |
| Aoyama, M | 1 |
| Tang, G | 1 |
| Duan, F | 1 |
| Li, W | 1 |
| Wang, Y | 3 |
| Zeng, C | 1 |
| Hu, J | 1 |
| Li, H | 2 |
| Zhang, X | 3 |
| Chen, Y | 3 |
| Tan, H | 1 |
| Seneviratne, A | 1 |
| Cave, L | 1 |
| Hyde, G | 1 |
| Moestrup, SK | 1 |
| Carling, D | 2 |
| Mason, JC | 2 |
| Haskard, DO | 2 |
| Boyle, JJ | 2 |
| Ye, Z | 1 |
| Găman, MA | 1 |
| Tan, SC | 1 |
| Zhu, F | 1 |
| Werida, R | 1 |
| Kabel, M | 1 |
| Omran, G | 1 |
| Shokry, A | 1 |
| Mostafa, T | 1 |
| Wu, H | 1 |
| Feng, K | 2 |
| Zhang, C | 1 |
| Zhang, H | 1 |
| Zhang, J | 2 |
| Hua, Y | 1 |
| Dong, Z | 1 |
| Zhu, Y | 2 |
| Yang, S | 2 |
| Ma, C | 2 |
| Feng, X | 1 |
| Chen, W | 2 |
| Ni, X | 1 |
| Little, PJ | 1 |
| Xu, S | 2 |
| Tang, L | 1 |
| Weng, J | 1 |
| Yan, N | 1 |
| Wang, L | 3 |
| Wang, T | 1 |
| Yang, L | 1 |
| Yan, R | 1 |
| Wang, H | 2 |
| Jia, S | 1 |
| Su, C | 1 |
| Li, X | 2 |
| Yang, Y | 3 |
| Du, Y | 1 |
| Hong, B | 1 |
| Liu, Q | 1 |
| Yang, M | 1 |
| Zhang, L | 2 |
| Zhang, R | 1 |
| Huang, X | 1 |
| Wang, X | 2 |
| Du, W | 1 |
| Hou, J | 1 |
| Tanaka, A | 1 |
| Shimabukuro, M | 1 |
| Okada, Y | 1 |
| Taguchi, I | 1 |
| Yamaoka-Tojo, M | 1 |
| Tomiyama, H | 1 |
| Teragawa, H | 1 |
| Sugiyama, S | 1 |
| Yoshida, H | 1 |
| Sato, Y | 1 |
| Kawaguchi, A | 1 |
| Ikehara, Y | 1 |
| Machii, N | 1 |
| Maruhashi, T | 1 |
| Shima, KR | 1 |
| Takamura, T | 1 |
| Matsuzawa, Y | 1 |
| Kimura, K | 1 |
| Sakuma, M | 1 |
| Oyama, JI | 1 |
| Inoue, T | 1 |
| Higashi, Y | 1 |
| Ueda, S | 1 |
| Node, K | 1 |
| Luo, F | 1 |
| Guo, Y | 1 |
| Ruan, GY | 1 |
| Long, JK | 1 |
| Zheng, XL | 1 |
| Xia, Q | 1 |
| Zhao, SP | 1 |
| Peng, DQ | 1 |
| Fang, ZF | 1 |
| Li, XP | 1 |
| Liu, X | 1 |
| Mei, T | 1 |
| Ye, S | 1 |
| Livingstone, R | 1 |
| Boyle, JG | 1 |
| Petrie, JR | 3 |
| Borowska, M | 1 |
| Dworacka, M | 1 |
| Winiarska, H | 1 |
| Krzyżagórska, E | 1 |
| Karnewar, S | 2 |
| Neeli, PK | 1 |
| Panuganti, D | 1 |
| Kotagiri, S | 1 |
| Mallappa, S | 1 |
| Jain, N | 1 |
| Jerald, MK | 1 |
| Kotamraju, S | 3 |
| Zhang, W | 1 |
| Yang, X | 1 |
| Liu, Y | 1 |
| Liu, L | 1 |
| Sun, L | 1 |
| Yu, M | 1 |
| Yang, J | 1 |
| Hu, W | 1 |
| Miao, RQ | 1 |
| Li, L | 1 |
| Han, J | 1 |
| Duan, Y | 1 |
| Yang, Q | 1 |
| Yuan, H | 1 |
| Qu, J | 1 |
| Yu, B | 1 |
| Chen, J | 1 |
| Sun, S | 1 |
| Tang, X | 1 |
| Ren, W | 1 |
| Gopoju, R | 1 |
| Panangipalli, S | 1 |
| Lim, S | 1 |
| Eckel, RH | 1 |
| Koh, KK | 1 |
| Jenkins, AJ | 2 |
| Welsh, P | 1 |
| Harrington, JL | 1 |
| de Albuquerque Rocha, N | 1 |
| Patel, KV | 1 |
| Verma, S | 1 |
| McGuire, DK | 1 |
| Lai, B | 1 |
| Li, Z | 1 |
| He, M | 1 |
| Chen, L | 2 |
| Shyy, JY | 2 |
| Peña, AS | 1 |
| Liew, G | 1 |
| Anderson, J | 1 |
| Giles, LC | 1 |
| Gent, R | 1 |
| Wong, TY | 1 |
| Couper, JJ | 1 |
| He, X | 1 |
| Chen, X | 1 |
| Wang, W | 1 |
| Liang, Q | 1 |
| Yi, L | 1 |
| Gao, Q | 1 |
| Peters, AS | 1 |
| Wortmann, M | 1 |
| Fleming, TH | 1 |
| Nawroth, PP | 1 |
| Bruckner, T | 1 |
| Böckler, D | 1 |
| Hakimi, M | 1 |
| Asai, A | 1 |
| Shuto, Y | 1 |
| Nagao, M | 1 |
| Kawahara, M | 1 |
| Miyazawa, T | 1 |
| Sugihara, H | 1 |
| Oikawa, S | 1 |
| Qu, RN | 1 |
| Qu, W | 1 |
| Nathan, DM | 1 |
| Bennett, PH | 1 |
| Crandall, JP | 1 |
| Edelstein, SL | 1 |
| Goldberg, RB | 1 |
| Kahn, SE | 1 |
| Knowler, WC | 1 |
| Mather, KJ | 1 |
| Mudaliar, S | 1 |
| Orchard, TJ | 1 |
| Temprosa, M | 1 |
| White, NH | 1 |
| Bajuk Studen, K | 1 |
| Jensterle Sever, M | 1 |
| Pfeifer, M | 1 |
| Wan, X | 1 |
| Huo, Y | 1 |
| Johns, M | 1 |
| Piper, E | 1 |
| Rosiak, M | 1 |
| Postula, M | 1 |
| Kaplon-Cieslicka, A | 1 |
| Trzepla, E | 1 |
| Czlonkowski, A | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Mathew, G | 1 |
| Thambi, M | 1 |
| Unnikrishnan, MK | 1 |
| Hayashi, T | 2 |
| Kotani, H | 1 |
| Yamaguchi, T | 2 |
| Taguchi, K | 1 |
| Iida, M | 1 |
| Ina, K | 1 |
| Maeda, M | 1 |
| Kuzuya, M | 1 |
| Hattori, Y | 2 |
| Ignarro, LJ | 1 |
| Bułdak, Ł | 1 |
| Łabuzek, K | 1 |
| Bułdak, RJ | 1 |
| Kozłowski, M | 1 |
| Machnik, G | 1 |
| Liber, S | 1 |
| Suchy, D | 1 |
| Duława-Bułdak, A | 1 |
| Okopień, B | 1 |
| Riksen, NP | 1 |
| Tack, CJ | 1 |
| Forouzandeh, F | 1 |
| Salazar, G | 1 |
| Patrushev, N | 1 |
| Xiong, S | 1 |
| Hilenski, L | 1 |
| Fei, B | 1 |
| Alexander, RW | 1 |
| Vasamsetti, SB | 1 |
| Kanugula, AK | 1 |
| Thatipalli, AR | 1 |
| Kumar, JM | 1 |
| Dimova, R | 1 |
| Tankova, T | 1 |
| Hattori, K | 1 |
| Kurdi, A | 1 |
| De Meyer, GR | 1 |
| Martinet, W | 1 |
| Lankin, VZ | 1 |
| Tikhaze, AK | 1 |
| Chaturvedi, N | 1 |
| Ford, I | 1 |
| Hramiak, I | 1 |
| Hughes, AD | 1 |
| E Klein, B | 1 |
| Klein, R | 1 |
| Ooi, TC | 1 |
| Rossing, P | 1 |
| Sattar, N | 1 |
| Stehouwer, CD | 1 |
| Colhoun, HM | 1 |
| Ma, A | 2 |
| Wang, D | 1 |
| An, Y | 1 |
| Fang, W | 1 |
| Zhu, H | 2 |
| Wang, J | 1 |
| Zhao, M | 1 |
| Huang, NL | 1 |
| Chiang, SH | 1 |
| Hsueh, CH | 1 |
| Liang, YJ | 1 |
| Chen, YJ | 1 |
| Lai, LP | 1 |
| Papanas, N | 1 |
| Maltezos, E | 1 |
| Shwarts, V | 1 |
| Zhang, XY | 1 |
| Du, JL | 1 |
| Jia, YJ | 1 |
| Bai, R | 1 |
| Ba, Y | 1 |
| Xing, Q | 1 |
| Men, LL | 1 |
| Song, J | 1 |
| Ren, P | 1 |
| Wang, XL | 1 |
| Shen, YH | 1 |
| Li, SN | 1 |
| Zeng, QT | 1 |
| Feng, YB | 1 |
| Cheng, X | 1 |
| Mao, XB | 1 |
| Wang, TH | 1 |
| Deng, HP | 1 |
| Kanazawa, I | 1 |
| Yano, S | 1 |
| Yamamoto, M | 1 |
| Yamauchi, M | 1 |
| Kurioka, S | 1 |
| Sugimoto, T | 1 |
| Liao, YF | 1 |
| Chen, LL | 1 |
| Zeng, TS | 1 |
| Li, YM | 1 |
| Hu, LJ | 1 |
| Mohan, V | 1 |
| Ravikumar, R | 1 |
| Poongothai, S | 1 |
| Amutha, A | 1 |
| Sowmya, S | 1 |
| Karkhuzali, K | 1 |
| Parkin, CG | 1 |
| Tan, BK | 1 |
| Adya, R | 1 |
| Shan, X | 1 |
| Aghilla, M | 1 |
| Lehnert, H | 1 |
| Keay, SD | 1 |
| Randeva, HS | 1 |
| Tousoulis, D | 1 |
| Koniari, K | 1 |
| Antoniades, C | 1 |
| Miliou, A | 1 |
| Noutsou, M | 1 |
| Nikolopoulou, A | 1 |
| Papageorgiou, N | 1 |
| Marinou, K | 1 |
| Stefanadi, E | 1 |
| Stefanadis, C | 1 |
| Mihaylova, MM | 1 |
| Zheng, B | 1 |
| Hou, X | 1 |
| Jiang, B | 1 |
| Park, O | 1 |
| Luo, Z | 1 |
| Lefai, E | 1 |
| Gao, B | 1 |
| Wierzbicki, M | 1 |
| Verbeuren, TJ | 1 |
| Shaw, RJ | 1 |
| Cohen, RA | 1 |
| Zang, M | 1 |
| Ghatak, SB | 1 |
| Dhamecha, PS | 1 |
| Bhadada, SV | 1 |
| Panchal, SJ | 1 |
| Fitch, K | 1 |
| Abbara, S | 1 |
| Lee, H | 1 |
| Stavrou, E | 1 |
| Sacks, R | 1 |
| Michel, T | 1 |
| Hemphill, L | 1 |
| Torriani, M | 1 |
| Grinspoon, S | 1 |
| Kuller, LH | 1 |
| Klempfner, R | 1 |
| Leor, J | 1 |
| Tenenbaum, A | 1 |
| Fisman, EZ | 1 |
| Goldenberg, I | 1 |
| Mongraw-Chaffin, ML | 1 |
| Matsushita, K | 1 |
| Brancati, FL | 1 |
| Astor, BC | 1 |
| Coresh, J | 1 |
| Crawford, SO | 1 |
| Schmidt, MI | 1 |
| Hoogeveen, RC | 1 |
| Ballantyne, CM | 1 |
| Young, JH | 1 |
| Machado, AP | 1 |
| Pinto, RS | 1 |
| Moysés, ZP | 1 |
| Nakandakare, ER | 1 |
| Quintão, EC | 1 |
| Passarelli, M | 1 |
| Isoda, K | 1 |
| Young, JL | 1 |
| Zirlik, A | 1 |
| MacFarlane, LA | 1 |
| Tsuboi, N | 1 |
| Gerdes, N | 1 |
| Schönbeck, U | 1 |
| Libby, P | 1 |
| Glueck, CJ | 1 |
| Aregawi, D | 1 |
| Agloria, M | 1 |
| Winiarska, M | 1 |
| Sieve, L | 1 |
| Wang, P | 1 |
| Stocker, DJ | 1 |
| Taylor, AJ | 1 |
| Langley, RW | 1 |
| Jezior, MR | 1 |
| Vigersky, RA | 1 |
| Bradbury, RA | 1 |
| Samaras, K | 1 |
| García-Moll, X | 1 |
| Cho, LW | 1 |
| Atkin, SL | 1 |
| Wild, RA | 1 |
| Bailey, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560] | Phase 4 | 80 participants (Actual) | Interventional | 2018-10-08 | Completed | ||
| The Emirates Heart Health Project: A Stepped-wedge Cluster Randomized-controlled Trial of a Family-based Health Coach Guided Dietary and Exercise Intervention for Reducing Weight and Cardiovascular Risk in Overweight and Obese Adult Nationals of the Unite[NCT04688684] | 80 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | |||
| Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection[NCT04267809] | Phase 2 | 44 participants (Anticipated) | Interventional | 2021-10-22 | Recruiting | ||
| Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial[NCT01410604] | Phase 4 | 31 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Strategies for the Treatment of HIV Associated Metabolic Syndrome[NCT00399360] | 50 participants (Actual) | Interventional | 2006-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in Adiponectin after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | µg/mL (Mean) |
|---|---|
| Metformin | -0.71 |
| Placebo | -7.52 |
Change from baseline in Body Mass Index after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Metformin | -0.74 |
| Placebo | -0.71 |
Change from baseline in Fasting insulin after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | µU/mL (Mean) |
|---|---|
| Metformin | -3.97 |
| Placebo | 11.03 |
Change from baseline in Fasting plasma glucose after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin | -1.08 |
| Placebo | 1.71 |
Change from baseline in High-sensitivity C-reactive protein after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin | -1.26 |
| Placebo | -1.35 |
Change from baseline in Interleukin 6 after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Metformin | -34.09 |
| Placebo | 16.42 |
Change from baseline in Tumour necrosis factor alpha after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Metformin | -34.08 |
| Placebo | -4.01 |
Change from baseline in Waist circumference after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | cm (Mean) |
|---|---|
| Metformin | -0.57 |
| Placebo | -3.29 |
Abdominal visceral adipose area was assess by magnetic resonance imaging at the lvel of the L4 pedicle. The change in abdominal visceral adiposity between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | cm2 (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -22.6 |
| Lifestyle Modification and Placebo | -1.5 |
| No Lifestyle Modification and Metformin | -28.2 |
| Lifestyle Modification and Metformin | -35.0 |
High sensitivity C-reactive protein was determined by R&D Systems (Minneapolis, MN) kit. The change in C-reactive protein between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/l (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.27 |
| Lifestyle Modification and Placebo | -1.19 |
| No Lifestyle Modification and Metformin | 0.47 |
| Lifestyle Modification and Metformin | -1.92 |
A submaximal exercise stress test was conducted on a cycle ergometer to measure endurance. Subjects cycled between 50-60 revolutions per minute and the workload was progressively increased in increments of 50 watts in stages lasting 3 minutes. Once subjects became fatigued or reached their submaximal heart rate (220-age x 85), the test was stopped and separate readings of heart rate and blood pressure were measured at 1, 3, and 5 min of recovery. Weight-adjusted maximum oxygen consumption (VO2max; ml/kg per minute) was determined. The change in cardiorespiratory fitness between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | ml/kg/min (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.7 |
| Lifestyle Modification and Placebo | 2.0 |
| No Lifestyle Modification and Metformin | -1.3 |
| Lifestyle Modification and Metformin | 3.7 |
Carotid intima media thickness imaging of the common carotid artery was conducted using a high-resolution 7.5-MHz phased-array transducer (SONOS 2000/2500. The change of the carotid intima media thickness measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mm (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.02 |
| Lifestyle Modification and Placebo | -0.02 |
| No Lifestyle Modification and Metformin | 0.00 |
| Lifestyle Modification and Metformin | 0.03 |
Computed tomography (CT) imaging was performed using a SOMATOM Sensation (Siemens Medical Solutions, Forcheim, Germany) 64-slice CT scanner. Agatston calcium score was calculated using CT images. The total Agatston score is calculated by summing up the scores of the individual calcifications in all slices of the CT scan. An absolute Agatston score of less than 10 indicates minimal overall atherosclerosis (plaques) in the coronary arteries. The change in the coronary artery calcium score between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | Agatston score (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | 43 |
| Lifestyle Modification and Placebo | 19 |
| No Lifestyle Modification and Metformin | 1 |
| Lifestyle Modification and Metformin | -4 |
Glucose level was determined after an overnight fast. The change in glucose between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -7 |
| Lifestyle Modification and Placebo | 3 |
| No Lifestyle Modification and Metformin | 2 |
| Lifestyle Modification and Metformin | -7 |
High density lipoprotein (HDL) was determined after an overnight fast. The change in HDL between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -2 |
| Lifestyle Modification and Placebo | 2 |
| No Lifestyle Modification and Metformin | 0 |
| Lifestyle Modification and Metformin | 4 |
Intramyocellular lipid (IMCL) of the tibialis anterior was determined using 1H-magnetic resonance spectroscopy (Siemens, Munich, Germany). The change in the intramyocellular lipid measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mmol/kg (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | 0.6 |
| Lifestyle Modification and Placebo | -0.4 |
| No Lifestyle Modification and Metformin | 0.8 |
| Lifestyle Modification and Metformin | 0.1 |
Systolic blood pressure was measured after 5 minutes rest. The in systolic blood pressure between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mm Hg (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -5 |
| Lifestyle Modification and Placebo | -2 |
| No Lifestyle Modification and Metformin | -2 |
| Lifestyle Modification and Metformin | -6 |
Iliac waist circumference measurements were obtained using an inelastic tape measure. All measurements were obtained in triplicate, with the patient undressed, and then averaged. The change of the waist circumference measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | cm (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -1.9 |
| Lifestyle Modification and Placebo | -0.1 |
| No Lifestyle Modification and Metformin | 0.3 |
| Lifestyle Modification and Metformin | -1.4 |
19 reviews available for metformin and Atherogenesis
| Article | Year |
|---|---|
From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; | 2022 |
Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; | 2023 |
The effect of metformin on carotid intima-media thickness (CIMT): A systematic review and meta-analysis of randomized clinical trials.
Topics: Atherosclerosis; Carotid Intima-Media Thickness; Humans; Hypoglycemic Agents; Metformin; Randomized | 2020 |
Metformin, Macrophage Dysfunction and Atherosclerosis.
Topics: Animals; Atherosclerosis; Biomarkers; Cardiometabolic Risk Factors; Cell Plasticity; Diabetes Compli | 2021 |
A new perspective on metformin therapy in type 1 diabetes.
Topics: Atherosclerosis; Cholesterol; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Metformin | 2017 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Disea | 2018 |
Metformin, lipids and atherosclerosis prevention.
Topics: Atherosclerosis; Blood Vessels; Humans; Lipid Metabolism; Metformin | 2018 |
Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach.
Topics: Atherosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; M | 2018 |
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes | 2019 |
Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenes; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thick | 2013 |
The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis.
Topics: Adipokines; Age Factors; Animals; Atherosclerosis; Gene Expression Regulation; Glucose Metabolism Di | 2015 |
Potential therapeutic effects of mTOR inhibition in atherosclerosis.
Topics: Animals; Atherosclerosis; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inh | 2016 |
Role of Oxidative Stress in the Genesis of Atherosclerosis and Diabetes Mellitus: A Personal Look Back on 50 Years of Research.
Topics: Aging; Animals; Antioxidants; Atherosclerosis; Diabetes Mellitus; Free Radicals; Glucose; Humans; Hy | 2017 |
Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
Topics: Acarbose; Administration, Oral; Animals; Atherosclerosis; Biomarkers; Blood Glucose; Cardiovascular | 2009 |
[Adipose tissue inflammation and atherosclerosis].
Topics: Adipokines; Adipose Tissue; Atherosclerosis; Chemotaxis; Cytokines; Endothelium, Vascular; Humans; H | 2009 |
Metformin use among individuals at risk for type 2 diabetes.
Topics: Atherosclerosis; Blood Glucose; Diabetes Mellitus, Type 2; Early Diagnosis; Fasting; Female; Humans; | 2012 |
Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?
Topics: Antiretroviral Therapy, Highly Active; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, | 2008 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exerci | 2007 |
Metformin: effects on micro and macrovascular complications in type 2 diabetes.
Topics: Animals; Atherosclerosis; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus | 2008 |
13 trials available for metformin and Atherogenesis
| Article | Year |
|---|---|
Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: A randomized controlled trial.
Topics: Adolescent; Atherosclerosis; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Carotid Int | 2022 |
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
Topics: Adiponectin; Atherosclerosis; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, | 2020 |
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Benzhydryl Compounds; Blood Pressure; Diabetes Mell | 2017 |
Homocysteine as a non-classical risk factor for atherosclerosis in relation to pharmacotherapy of type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Diabetes Mellitus, Type 2; Female; Homocysteine; Humans; H | 2017 |
Early atherosclerosis is associated with retinal microvascular changes in adolescents with type 1 diabetes.
Topics: Adolescent; Age of Onset; Atherosclerosis; Child; Cross-Sectional Studies; Diabetes Mellitus, Type 1 | 2018 |
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.
Topics: Adult; Atherosclerosis; Blood Glucose; Body Weight; Carotid Intima-Media Thickness; Cholesterol, LDL | 2017 |
[Primary preventive effect of metformin upon atherosclerosis in patients with type 2 diabetes mellitus].
Topics: Adult; Aged; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypo | 2009 |
Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus.
Topics: Aged; Atherosclerosis; Biomarkers; Blood Glucose; Body Weight; Bone Density; Collagen; Diabetes Mell | 2010 |
A single-center, open, comparative study of the effect of using self-monitoring of blood glucose to guide therapy on preclinical atherosclerotic markers in type 2 diabetic subjects.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; | 2010 |
Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study.
Topics: Atherosclerosis; Atorvastatin; Blood Flow Velocity; Blood Glucose; Body Mass Index; Diabetes Mellitu | 2010 |
Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Female; HIV Infections; Humans; Hypoglycemic Agents; Life | 2012 |
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.
Topics: Adamantane; Adiponectin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; | 2012 |
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease | 2007 |
46 other studies available for metformin and Atherogenesis
| Article | Year |
|---|---|
Topics: Acanthaceae; Animals; Atherosclerosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; D | 2021 |
How Diabetes and Other Comorbidities of Elderly Patients and Their Treatment Influence Levels of Glycation Products.
Topics: Aged; Amines; Atherosclerosis; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Humans; | 2022 |
Effect of different antidiabetic medications on atherosclerotic cardiovascular disease (ASCVD) risk score among patients with type-2 diabetes mellitus: A multicenter non-interventional observational study.
Topics: Atherosclerosis; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglyc | 2022 |
Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus.
Topics: Ankle Brachial Index; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Elasticity; En | 2022 |
AMPK activators suppress cholesterol accumulation in macrophages via suppression of the mTOR pathway.
Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; ATP Binding Cassette Transporter 1; Cholest | 2023 |
Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE
Topics: Adenylate Kinase; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blood Glucose; Carrier Protein | 2019 |
Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase.
Topics: Activating Transcription Factor 1; AMP-Activated Protein Kinases; Animals; Aorta; Aortic Diseases; A | 2021 |
Metformin attenuates atherosclerosis and plaque vulnerability by upregulating KLF2-mediated autophagy in apoE
Topics: Animals; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; Autophagy; Cholesterol; Diet, High-Fa | 2021 |
Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Dysbiosis; Fatty Acids, Volat | 2021 |
Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality.
Topics: Akkermansia; Animals; Atherosclerosis; Bifidobacterium; Choline; Diabetes Mellitus, Type 2; Diet; Dy | 2021 |
Metformin inhibits cholesterol‑induced adhesion molecule expression via activating the AMPK signaling pathway in vascular smooth muscle cells.
Topics: AMP-Activated Protein Kinases; Atherosclerosis; Cell Adhesion Molecules; Cholesterol; Humans; Interc | 2021 |
Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; Biopsy; Cholesterol; Diet, High-Fat; Disease Mod | 2017 |
Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients.
Topics: Adult; Atherosclerosis; Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Dr | 2017 |
Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: Relevance in age-associated vascular dysfunction.
Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Cellular Senescence; Endothelial Cells; His | 2018 |
Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy.
Topics: AMP-Activated Protein Kinases; Animals; Aorta; Apolipoproteins E; Atherosclerosis; ATP Binding Casse | 2018 |
Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses in rabbits.
Topics: Animals; Aorta; Atherosclerosis; C-Reactive Protein; Cell Adhesion; Cell Differentiation; Cell Line, | 2018 |
Metformin treatment prevents SREBP2-mediated cholesterol uptake and improves lipid homeostasis during oxidative stress-induced atherosclerosis.
Topics: Animals; Aorta; Atherosclerosis; Cells, Cultured; Cholesterol; Homeostasis; Humans; Hypoglycemic Age | 2018 |
Atheroprone flow enhances the endothelial-to-mesenchymal transition.
Topics: AMP-Activated Protein Kinases; Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Cadherins; Cell | 2018 |
Metformin ameliorates Ox-LDL-induced foam cell formation in raw264.7 cells by promoting ABCG-1 mediated cholesterol efflux.
Topics: Animals; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 1; Cholesterol; Cyto | 2019 |
Effect of metformin treatment in patients with type 2 diabetes with respect to glyoxalase 1 activity in atherosclerotic lesions.
Topics: Aged; Atherosclerosis; Diabetes Mellitus, Type 2; Female; Humans; Lactoylglutathione Lyase; Male; Me | 2019 |
Metformin Attenuates Early-Stage Atherosclerosis in Mildly Hyperglycemic Oikawa-Nagao Mice.
Topics: Animals; Atherosclerosis; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Hyperglycem | 2019 |
Metformin inhibits LPS-induced inflammatory response in VSMCs by regulating TLR4 and PPAR-γ.
Topics: Animals; Atherosclerosis; Cells, Cultured; Chemokine CCL2; Down-Regulation; Drug Evaluation, Preclin | 2019 |
5'-AMP-activated protein kinase-activating transcription factor 1 cascade modulates human monocyte-derived macrophages to atheroprotective functions in response to heme or metformin.
Topics: Activating Transcription Factor 1; AMP-Activated Protein Kinases; Atherosclerosis; Heme; Heme Oxygen | 2013 |
Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Aged; Atherosclerosis; Biguanides; Cardiovascular Diseases; Coronary Ar | 2013 |
A multimodal Darwinian strategy for alleviating the atherosclerosis pandemic.
Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Biological Evolution; Humans; Hygiene; Inte | 2014 |
Endothelial cellular senescence is inhibited by liver X receptor activation with an additional mechanism for its atheroprotection in diabetes.
Topics: Administration, Oral; Animals; Aorta; Atherosclerosis; Cellular Senescence; Densitometry; Diabetes C | 2014 |
Metformin affects macrophages' phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages.
Topics: AMP-Activated Protein Kinases; Antioxidants; Atherosclerosis; Catalase; Cytokines; Female; Glutathio | 2014 |
The cardiovascular effects of metformin: lost in translation?
Topics: Animals; Atherosclerosis; Atrial Remodeling; Carotid Intima-Media Thickness; Clinical Trials as Topi | 2014 |
Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Blood Glucose; Cardiovascular A | 2014 |
Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis.
Topics: AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Cell Differentiation; Ma | 2015 |
Pleiotropic benefits of metformin: macrophage targeting its anti-inflammatory mechanisms.
Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Macrophages; Male; Metformin; Monocytes; ST | 2015 |
Comparative transcriptomic analysis of mice liver treated with different AMPK activators in a mice model of atherosclerosis.
Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Diet, High-Fat; Disease Models, Animal; Liv | 2017 |
AMPK activation reduces the number of atheromata macrophages in ApoE deficient mice.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antigens, Ly; Aorta; Aortic Dise | 2017 |
Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation.
Topics: AMP-Activated Protein Kinases; Anti-Inflammatory Agents; Atherosclerosis; Cells, Cultured; Endotheli | 2009 |
Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4.
Topics: Atherosclerosis; Carnitine O-Palmitoyltransferase; Cell Line, Tumor; Down-Regulation; Fatty Acid-Bin | 2010 |
Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Biomarkers; Blood Glucose; Blotting, West | 2009 |
Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes.
Topics: Adult; Atherosclerosis; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Ce | 2010 |
The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis.
Topics: Adipokines; Adipose Tissue; Adult; Animals; Atherosclerosis; Case-Control Studies; Female; Humans; I | 2011 |
AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice.
Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Benzopyrans; Dietary Fats; Disease Models, | 2011 |
Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats.
Topics: Animals; Antioxidants; Aorta; Atherosclerosis; Blood Coagulation; Body Weight; Carotid Arteries; Cho | 2011 |
Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Blood Glucose; Cohort Studies; Cross-Sectional Studies; Di | 2012 |
Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products.
Topics: Albumins; Animals; Atherosclerosis; Cells, Cultured; Cholesterol, HDL; Diabetes Mellitus; Enzyme Inh | 2006 |
Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Cell Survival; Cells, Cultured; Diabetes Mellitus, Type 2 | 2006 |
Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Energy Intake; Female; Humans; | 2006 |
[Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?].
Topics: Acute Coronary Syndrome; Atherosclerosis; Biometry; Dyslipidemias; Fluorobenzenes; Humans; Hydroxyme | 2007 |
Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: counterpoint.
Topics: Adult; Atherosclerosis; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hyperlipidemias; Metfor | 2008 |